HDAC inhibitor-based therapies: can we interpret the code?

HDAC inhibitor-based therapies: can we interpret the code?

Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...

Bibliografski detalji
Glavni autori:	New, M, Olzscha, H, La Thangue, N
Format:	Journal article
Jezik:	English
Izdano:	2012

Slični predmeti

The TLR adaptor protein MyD88 mediates cell sensitivity to HDAC inhibitors through a cytokine-dependent mechanism
od: Sheikh, S, i dr.
Izdano: (2016)

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
od: New, M, i dr.
Izdano: (2013)

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
od: New, M, i dr.
Izdano: (2013)

HDAC inhibitor-based therapies and haematological malignancy.
od: Stimson, L, i dr.
Izdano: (2009)

TLR adaptor protein MYD88 mediates sensitivity to HDAC inhibitors via a cytokine-dependent mechanism
od: New, M, i dr.
Izdano: (2016)

Biomarkers for predicting clinical responses to HDAC inhibitors.
od: Stimson, L, i dr.
Izdano: (2009)

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
od: Khan, O, i dr.
Izdano: (2012)

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
od: Khan, O, i dr.
Izdano: (2010)

Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
od: Linda Anna Michelle Kulka, i dr.
Izdano: (2020-06-01)

Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
od: New, M
Izdano: (2014)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
od: Liu, G, i dr.
Izdano: (2023)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
od: Wiktoria Blaszczak, i dr.
Izdano: (2021-12-01)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
od: Geng Liu, i dr.
Izdano: (2023-01-01)

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
od: Fotheringham, S, i dr.
Izdano: (2009)

Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy
od: Miranda E Clements, i dr.
Izdano: (2023-03-01)

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
od: Khan, O, i dr.
Izdano: (2008)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
od: Cristina Maccallini, i dr.
Izdano: (2022-05-01)

CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation
od: Olzscha, H, i dr.
Izdano: (2016)

Bromodomains control amyloid-like aggregation of aberrantly acetylated proteins
od: Olzscha, H, i dr.
Izdano: (2018)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
od: Jacob King, i dr.
Izdano: (2021-11-01)

Can We Interpret Implicitness?
od: Dilem Dinc, i dr.
Izdano: (2023-12-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
od: Elizabeth A. Thomas
Izdano: (2014-05-01)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
od: Zsófia Kutil, i dr.
Izdano: (2019-11-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
od: Wanli Zhang, i dr.
Izdano: (2025-02-01)

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition
od: Jing Zhou, i dr.
Izdano: (2023-07-01)

The efficacy of HDAC inhibitors in neoplasm treatment
od: Dominika Psiuk, i dr.
Izdano: (2020-08-01)

Current HDAC Inhibitors in Clinical Trials
od: Elisabetta Di Bello, i dr.
Izdano: (2022-05-01)

The Effect of Quisinostat as the HDAC Inhibitor on Migration
od: Marjan Hajimoradi Javarsiani, i dr.
Izdano: (2021-08-01)

The Effect of Quisinostat as the HDAC Inhibitor on Migration
od: Marjan Hajimoradi Javarsiani, i dr.
Izdano: (2021-08-01)

Phosphorus containing analogues of SAHA as inhibitors of HDACs
od: Michael D. Pun, i dr.
Izdano: (2022-12-01)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
od: Sophia G Liva, i dr.
Izdano: (2020-01-01)

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice
od: Alessandra Tammaro, i dr.
Izdano: (2024-01-01)

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
od: Lourdes Hontecillas-Prieto, i dr.
Izdano: (2020-09-01)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
od: Mohamed D. M. Traoré, i dr.
Izdano: (2017-04-01)

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S. mansoni larval and adult worm stages.
od: Roberto Gimmelli, i dr.
Izdano: (2024-02-01)

HDAC Inhibitors: Innovative Strategies for Their Design and Applications
od: Mateusz Daśko, i dr.
Izdano: (2022-01-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
od: Ehab Ghazy, i dr.
Izdano: (2022-01-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
od: Laurence Booth, i dr.
Izdano: (2019-07-01)

Diversity within the pRb pathway: is there a code of conduct?
od: Munro, S, i dr.
Izdano: (2012)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
od: Beatriz Silva Urias, i dr.
Izdano: (2022-10-01)